Inactivation analysis of SARS-CoV-2 by specimen transport media, nucleic acid extraction reagents, detergents and fixatives
Stephen Welch, Katherine Davies, Hubert Buczkowski, Nipunadi Hettiarachchi, Nicole Green, Ulrike Arnold, Matthew Jones, Matthew J Hannah, Reah Evans, Christopher Burton, Jane E Burton, Malcolm Guiver, Patricia A Cane, Neil Woodford, Christine B Bruce, Allen D.G Roberts, Marian J Killip
Abstract
The COVID-19 pandemic has necessitated a rapid multi-faceted response by the scientific community, bringing researchers, health officials and industry together to address the ongoing public health emergency. To meet this challenge, participants need an informed approach for working safely with the etiological agent, the novel human coronavirus SARS-CoV-2. Work with infectious SARS-CoV-2 is currently restricted to high-containment laboratories, but material can be handled at a lower containment level after inactivation. Given the wide array of inactivation reagents that are being used in laboratories during this pandemic, it is vital that their effectiveness is thoroughly investigated. Here, we evaluated a total of 23 commercial reagents designed for clinical sample transportation, nucleic acid extraction and virus inactivation for their ability to inactivate SARS-CoV-2, as well as seven other common chemicals including detergents and fixatives. As part of this study, we have also tested five filtration matrices for their effectiveness at removing the cytotoxic elements of each reagent, permitting accurate determination of levels of infectious virus remaining following treatment. In addition to providing critical data informing inactivation methods and risk assessments for diagnostic and research laboratories working with SARS-CoV-2, these data provide a framework for other laboratories to validate their inactivation processes and to guide similar studies for other pathogens.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Assessment of Inactivation Procedures for SARS-CoV-2
H. Auerswald, S. Yann, … J. A. Garcia-Rivera·bioRxiv·May 28, 2020
- Methods of inactivation of SARS-CoV-2 for downstream biological assays
E. I. Patterson, T. Prince, … G. L. Hughes·bioRxiv·May 21, 2020
- Inactivation of SARS Coronavirus 2 and COVID-19 patient samples for contemporary immunology and metabolomics studies
D. J. Eddins, L. C. Bassit, … E. Ghosn·bioRxiv·Oct 22, 2021
- Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
S. Westhaus, M. Widera, … S. Ciesek·bioRxiv·Sep 11, 2020
- Evaluation of the SARS-CoV-2 inactivation efficacy associated with buffers from three kits used on high-throughput RNA extraction platforms
R. E. Thom, L. Eastaugh, … S. A. Weller·bioRxiv·Apr 14, 2021
- Propagation, inactivation, and safety testing of SARS-CoV-2
A. S. Jureka, J. A. Silvas, C. F. Basler·VirusesPeer-reviewed·Jun 6, 2020